Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

about

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

Item

http://www.wikidata.org/entity/Q36983722

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

@en

type

Item

label

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

@en

prefLabel

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

@en

P1476

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

@en

P2093

Abdülkadir Ünsal

http://www.w3.org/2001/XMLSchema#string

Alaattin Yıldız

http://www.w3.org/2001/XMLSchema#string

Belda Dursun

http://www.w3.org/2001/XMLSchema#string

Ekrem Doğan

http://www.w3.org/2001/XMLSchema#string

Ertuğrul Akbaş

http://www.w3.org/2001/XMLSchema#string

Fatih Özdener

http://www.w3.org/2001/XMLSchema#string

Lütfullah Altıntepe

http://www.w3.org/2001/XMLSchema#string

Murat Duranay

http://www.w3.org/2001/XMLSchema#string

Rümeyza Kazancıoğlu

http://www.w3.org/2001/XMLSchema#string

Sedat Üstündağ

http://www.w3.org/2001/XMLSchema#string

P2860

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis

The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease.

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.

C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.

[Efficacy and safety of CERA in anemia correction in predialysis patients--Croatian experience].

P304

322-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5152/BALKANMEDJ.2016.141173

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27308077

http://www.w3.org/2001/XMLSchema#string

P932

4898992

http://www.w3.org/2001/XMLSchema#string